Increase the Tirzepatide Dose
If a patient tolerates 7.5 mg weekly tirzepatide without appetite suppression, escalate to the next dose level (10 mg weekly) after 4 weeks at the current dose.
Rationale for Dose Escalation
The standard tirzepatide titration protocol requires gradual dose increases to reach therapeutic effect. The 7.5 mg dose is not a maintenance dose—it is an intermediate step in the escalation schedule 1, 2. Clinical trials demonstrate a clear dose-response relationship: weight loss at 72 weeks was 15.0% with 5 mg, 19.5% with 10 mg, and 20.9% with 15 mg, compared to 3.1% with placebo 1, 3. The appetite suppression and metabolic benefits increase substantially with higher doses.
Specific Titration Algorithm
Follow this structured approach:
- Week 0-4: Start at 2.5 mg weekly
- Week 4-8: Increase to 5 mg weekly
- Week 8-12: Increase to 7.5 mg weekly (current position)
- Week 12-16: Advance to 10 mg weekly (next step for this patient)
- Week 16+: Consider 15 mg weekly if 10 mg response is suboptimal
The 20-week dose-escalation period is designed to minimize gastrointestinal adverse effects while achieving therapeutic efficacy 2, 3.
Why Lack of Appetite Suppression at 7.5 mg is Expected
Recent mechanistic data show tirzepatide reduces energy intake by approximately 525 kcal at therapeutic doses, with effects on overall appetite, food cravings, and tendency to overeat 4. However, some patients achieve strong responses only at submaximal or maximal doses 2. One real-world case report specifically documented that 7.5 mg produced an "undulating pattern" where appetite suppression was inconsistent, with the patient intermittently experiencing neither satiety nor delayed digestion 5. This supports that 7.5 mg may be insufficient for consistent therapeutic effect.
Key Implementation Points
- Do not remain at 7.5 mg indefinitely—this dose is part of the escalation phase, not a stopping point
- Tolerance without efficacy signals the need to advance, not to discontinue or switch therapies
- The target maintenance doses are 10 mg or 15 mg weekly where maximal weight loss and appetite regulation occur 1, 3
- In the pivotal SURMOUNT-1 trial, 89% of patients on 10 mg and 91% on 15 mg achieved ≥5% weight loss, compared to only 85% on 5 mg 3
Common Pitfall to Avoid
Do not stop escalation prematurely. Some clinicians mistakenly treat intermediate doses as endpoints. The evidence clearly shows that 50-57% of patients achieve ≥20% weight loss only at the 10-15 mg doses, versus 3% with placebo 3. Stopping at 7.5 mg forfeits the majority of tirzepatide's therapeutic potential.
Monitoring During Escalation
After advancing to 10 mg:
- Assess appetite suppression, satiety, and food intake patterns at 4 weeks
- Monitor for gastrointestinal symptoms (nausea, diarrhea, vomiting)—these occur in ~12% of patients but are typically mild-to-moderate 6
- If 10 mg is well-tolerated but response remains suboptimal, advance to 15 mg after another 4 weeks
- Weight reduction should become evident within 4-8 weeks of reaching therapeutic doses